Latest News
Omeros Corporation
- Omeros: The Trade After European Rejection (NASDAQ:OMER)
- EU Panel Again Declines to Endorse Omeros Transplant Therapy
- Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
- Omeros Tumbles as EU Regulators Reaffirm Rejection of TA-TMA Drug Narsoplimab
- CHMP upholds rejection of Omeros’ narsoplimab despite US approval
- Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
- Why is Omeros stock sliding today?
- Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
- Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
- Omeros Corporation Stock Price Prediction: Today, Tomorrow, Next Week (OMER)
- Omeros Bros company wound up with debts alleged to exceed $2 million
- Omeros Corporation (OMER) Edges Lower to $18.90, Holding Above Key Support - Put Support
Headlines from the last 30 days, linking to the original publishers. See all market news →